|
Re: Zenith funding???
|
2
|
Zenith Epigenetics
|
Jun 17, 2019 05:00PM
|
|
Re: Zenith Financing Update
|
5
|
Zenith Epigenetics
|
May 13, 2016 11:47AM
|
|
Re: Zenith Epigentics and Resverlogix update 22 Jan 2018
|
4
|
Zenith Epigenetics
|
Feb 01, 2018 11:38AM
|
|
Re: Zenith Epigentics and Resverlogix update 22 Jan 2018
|
2
|
Resverlogix Corp.
|
Feb 01, 2018 11:39AM
|
|
Re: Zenith Epigenetics Corp. Commences Operations
|
7
|
Zenith Epigenetics
|
Dec 09, 2015 04:44PM
|
|
Re: Zenith Epigenetics Corp. Commences Operations
|
3
|
Zenith Epigenetics
|
Dec 08, 2015 01:02PM
|
|
Re: Zenith Epigenetics Corp. Commences Operations
|
5
|
Zenith Epigenetics
|
Dec 08, 2015 10:26PM
|
|
Re: Zenith Epigenetics Corp. Commences Operations
|
3
|
Zenith Epigenetics
|
Dec 09, 2015 12:35PM
|
|
Re: Zenith Epigenetics Corp. Announces Name Change & Corporate Reorganization
|
2
|
Zenith Epigenetics
|
Aug 02, 2016 01:31PM
|
|
Re: Zenith Epigenetics Corp. Announces Name Change & Corporate Reorganization
|
2
|
Zenith Epigenetics
|
Aug 02, 2016 02:07PM
|
|
Re: Zenith Epigenetics Announces Publication of Covalent Bromodomain Inhibitors, Offering a Novel Approach to Targeting BET Bromodomains
|
4
|
Zenith Epigenetics
|
Oct 02, 2018 10:27AM
|
|
Re: Zenith Epigenetics Announces Publication of Covalent Bromodomain Inhibitors, Offering a Novel Approach to Targeting BET Bromodomains
|
5
|
Zenith Epigenetics
|
Oct 01, 2018 09:57AM
|
|
Re: Zenith Epigenetics Announces Publication of a Case Study From its Ongoing mCRPC Clinical Study
|
3
|
Zenith Epigenetics
|
Sep 04, 2018 09:05AM
|
|
Re: Zenith Epigenetics Announces Publication of a Case Study From its Ongoing mCRPC Clinical Study
|
7
|
Zenith Epigenetics
|
Sep 04, 2018 09:46AM
|
|
Re: Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
|
5
|
Zenith Epigenetics
|
Oct 25, 2019 09:59AM
|
|
Re: Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
|
6
|
Zenith Epigenetics
|
Oct 18, 2019 12:56PM
|
|
Re: Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
|
7
|
Zenith Epigenetics
|
Sep 02, 2019 10:14AM
|
|
Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
|
4
|
Zenith Epigenetics
|
Mar 15, 2021 01:12PM
|
|
Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
|
3
|
Zenith Epigenetics
|
Mar 15, 2021 01:22PM
|
|
Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
|
8
|
Zenith Epigenetics
|
Mar 15, 2021 09:53PM
|
